Zhitong Financial App News, Ruibo Bio-B (06938.HK) announced that the European Medicines Agency (EMA) has approved the launch of Orbit-XI-AF, a phase 2b clinical trial to evaluate vortosiran (RBD4059). This is the world's first and most advanced small-interfering nucleic acid (siRNA) therapy targeting XI coagulation factor (FXI) for stroke prevention (SPAF) in patients with atrial fibrillation. The approval of this phase 2b multi-regional clinical trial (MRCT) marks an important milestone for vortosiran and highlights the global development strategy for the next generation of anticoagulants. This also enabled the company to advance the project to the next stage of global clinical development.

Zhitong Financial App News, Ruibo Bio-B (06938.HK) announced that the European Medicines Agency (EMA) has approved the launch of Orbit-XI-AF, a phase 2b clinical trial to evaluate vortosiran (RBD4059). This is the world's first and most advanced small-interfering nucleic acid (siRNA) therapy targeting XI coagulation factor (FXI) for stroke prevention (SPAF) in patients with atrial fibrillation. The approval of this phase 2b multi-regional clinical trial (MRCT) marks an important milestone for vortosiran and highlights the global development strategy for the next generation of anticoagulants. This also enabled the company to advance the project to the next stage of global clinical development.